Introduction {#Sec1}
============

Bladder cancer (BC) is the 9^th^ most common cancer in the United Kingdom and one of the most expensive malignancies to manage.^[@CR1],[@CR2]^ The disease is best stratified according to the presence of muscle invasion and cellular differentiation. Most BCs are non-muscle invasive (NMIBC) and have an excellent long-term prognosis.^[@CR3]^ NMIBC tumours are managed by endoscopic resection, intravesical chemotherapy and long-term surveillance.^[@CR4]^ Following initial treatment, many patients develop local recurrence, requiring further treatments.^[@CR5]^ Around 1/3 of tumours are muscle invasive BCs (MIBCs), requiring radical treatment if cure is to be obtained. Radical cystectomy (RC) or radiotherapy includes treatment of adjacent viscera with regional lymph nodes, and often includes systemic chemotherapy. The nature and toxicity of treatments and surveillance for BC can vary between patients, between each option and over time. There is evidence that treatment for MIBC can impact upon urinary function,^[@CR6]^ bowel function,^[@CR7]^ sexual function,^[@CR8],[@CR9]^ and affects body image,^[@CR10],[@CR11]^ which can lead to anxiety and depression.^[@CR7]^ However, there is less evidence regarding the consequences of treatment for NMIBC and the impact on patients\' Health-Related Quality of Life (HRQL).^[@CR12],[@CR13]^

The importance of large scale, population-level Patient-Reported Outcome Measures (PROMS) in improving healthcare design, patient experience and directing care is becoming recognised.^[@CR14],[@CR15]^ PROMS can be used to ascertain a more comprehensive understanding of the quality of survival, alongside the impact and relevance of health care provision, and as a surrogate measure within clinical trials. Previous research in the USA used a linkage database to identify BC patients and looked at results of 620 surveys completed before diagnosis and 856 completed after by patients ≥65 years old.^[@CR16]^ European PROMs work included 823 German patients of all ages and stages of BC.^[@CR13]^ These cross-sectional studies used generic PROMs or generic cancer PROMs.

To date, no large-scale surveys of BC patients have been conducted in the United Kindgom. As such, in 2013 the Department of Health (DH) England designed and administered a pilot survey of patients 1--5 years following their initial treatment for BC. Here we report the results of the pilot survey, which was conducted to identify a methodology to define the HRQL of individuals in the years following their treatment and to identify potential factors associated with poor outcomes.

Methods {#Sec2}
=======

Survey design {#Sec3}
-------------

The DH methodology has been described previously for cohorts diagnosed with non-Hodgkin's lymphoma, breast, colorectal and prostate cancer.^[@CR17]^ Individuals aged 16 or older surviving 1--5 years after a diagnosis of BC were identified via the Eastern Cancer Registration and Intelligence Centre (now part of National Cancer Registration and Analysis Service, NCRAS).^[@CR18]^ The sample size was chosen to match similar studies performed by the DH in other cancer sites.^[@CR17]^

Identified participants were mailed a questionnaire, with a covering letter from their treating Cancer Centre. Consent to participate was implied through return of completed questionnaires. Individuals who did not want to participate were asked to return their questionnaire uncompleted or to discard the survey. Two reminders were sent to non-responders. A Freephone helpline for patients was provided, which supported completion of the survey. Permission to approach patients without informed consent was given by the Health Research Authority (ref ECC 5-02(FT7)/2012).

Survey content {#Sec4}
--------------

Survey content included questions about treatment, disease status, generic HRQL (EQ-5D-5L) and BC specific outcomes (Functional Assessment of Cancer Therapy---Bladder (FACT-Bl)), social problems (Social Difficulties Inventory (SDI-21)), health and well-being in the past month, experience of care and presence of other long-term conditions (LTCs) (Supplementary File [1](#MOESM4){ref-type="media"}).

The EQ-5D-5L records problems on five domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).^[@CR19],[@CR20]^ There are five response options ranging from no problems to extreme problems. Respondents are asked to complete the response options based on how they are feeling that day.

The SDI-21 is a 21-item questionnaire, developed to assess everyday problems experienced by cancer patients.^[@CR21]^ Questions are answered on a scale of 0 (no difficulty) to 3 (very much), with respect to the past month. Sixteen of the items form three subscales: Everyday Living, Money Matters and Self and Others. These scales form a measure of social distress (SD-16), with scores ranging from 0 to 44.^[@CR22]^ The SDI-21 also comprises five single items.

FACT-Bl consists of the 27-item FACT-General (FACT-G) questionnaire^[@CR23]^ and 13 additional items. FACT-G covers four areas; Physical well-being, Social/family well-being, Emotional well-being and Functional well-being. The 13 additional items relate to urinary issues, bowel issues, appetite and weight, sexual items, body image, a question asking if the respondent has an ostomy appliance and two questions about ostomy appliances. All items ask about the last 7 days.

These surveys were chosen for inclusion as EQ-5D-5L, SDI-21 and Functional Assessment of Chronic Illness Therapy (FACIT) modules have been used in similar studies performed by the DH in other cancer sites.^[@CR17],[@CR14]^ Cognitive testing of all questionnaires was performed with a group of volunteer patients and expert panel review (clinicians/methodologists). In the final version of the survey, the team designing the survey removed the \'somewhat\' response option from FACT-Bl; changing the questionnaire from five responses to four.^[@CR18]^

Data handling {#Sec5}
-------------

All variables were derived from the survey data. Participants were asked if they had any other LTCs at the time of completing the questionnaire and to tick all conditions that they had from a list widely used in English DH surveys. This variable was categorised into none, 1, 2 or ≥3 LTCs. Information on self-reported disease status (in remission, treated but still present, not treated, recurrence, and not certain) and treatments (endoscopic/telescopic surgery with or without chemotherapy directly into the bladder, RC, chemotherapy, and radiotherapy) was taken from the questionnaire. Age was grouped into \<55 years, 55--64 years, 65--74 years, 75--85 years and ≥85 years.

EQ-5D-5L responses were split into people who reported at least one problem (of any severity) on any domain and people who reported having no problems on any domain. Individual domains were categorised in this way. A validated cutoff score of ≥10 on the SD-16 scale indicates a high level of social difficulties that requires follow-up by health or social care staff.^[@CR24]^ This was used in our analysis as a cutoff point (socially distressed v not socially distressed). Estimated cutoff points of 5 for the Everyday Living subscale, 2 for the Money Matters subscale and 3 for the Self and Others subscale were used in this study, as per previous research.^[@CR25]^ The five single items of the SDI-21 are scored individually.^[@CR22]^ As the \'somewhat\' option was removed from the questionnaire, FACT-Bl scores could not be calculated as per normal practice and thus cancer-specific questions from FACT-Bl were examined separately. FACT-Bl responses were grouped into those who responded \'not at all\' or \'a little\' and those who responded \'quite a bit\' and \'very much\'. Outcomes pertaining to well-being, urinary items, sexual items and body image are presented here.

Statistical analysis {#Sec6}
--------------------

Descriptive statistics were used to report respondent characteristics, EQ-5D-5L responses, SD-16 scores, SDI-21 subscale scores and FACT-Bl responses. Outcomes were analysed in relation to age, sex, other comorbidities and type of treatment using *χ*^2^ tests. Statistical significance was set at the 1% level to minimise the chances of false-positive associations. Analyses were performed using Stata version 15 (Stata, College Station, TX).

Results {#Sec7}
=======

Survey population {#Sec8}
-----------------

In total, 1252 BC patients were randomly identified and sent a questionnaire (Fig. [1](#Fig1){ref-type="fig"}). Of these, 21 (2%) died during the survey period, leaving 1231 eligible patients. Questionnaires were returned by 673 people (54% response rate), including 500 (74%) men and 162 (24%) women (Table [1](#Tab1){ref-type="table"}). Most respondents were white (93%) and were in remission from BC (65%). Co-existing LTCs were common (80% reported ≥1 LTC and 29% reported ≥3). The most common treatment was endoscopy/telescopy (31%). Radical treatment was reported by 28% of respondents: of which 14% had undergone RC, 9% had received external beam radiotherapy and 5% had radiotherapy with intravenous chemotherapy. Other treatment combinations were given to \<2% of respondents and therefore excluded from analysis. A stoma was present in 16% of respondents. Of the radical treatments, patients ≥85 years were more likely to be treated with radiotherapy (31%) (Supplementary Table [1](#MOESM1){ref-type="media"}).Fig. 1Design and response rates within this surveyTable 1Demographics of survey respondentsDemographicNo. of respondents%*Age, years* \<55537.9 55--6413720.4 65--7424736.7 75--8418427.3 ≥85355.2 No response172.5*Sex* Male50074.3 Female16224.1 Not known111.6*Race* White66799.1 Non white60.9*No. of long-term conditions (LTCs)* None11116.5 120530.4 214121.0 ≥319328.7 Not reported233.4*Disease status* Remission43464.5 Treated but cancer still present426.2 No treatment20.3 Recurrence304.5 Not certain8512.6 Not reported8011.9*Treatment* Endoscopy/telescopy20730.8 Endoscopy/telescopy with chemotherapy directly into the bladder19829.4 Radical cystectomy9213.7 Radiotherapy and Intravenous chemotherapy365.3 Radiotherapy639.4 Other487.1 Not reported294.3*Stoma status* Stoma10816.0 No stoma43765.0 Not reported12819.0

Respondent and non-respondent characteristics were compared, using data from NCRAS (Supplementary Table [2](#MOESM2){ref-type="media"}). Individuals older than 85 years (RR, 39%) were less likely to participate.

Data quality {#Sec9}
------------

Most patients answered questions relating to sex, LTCs and treatment (\<5% missing responses). Of all the PROMs, FACT-Bl had the largest variety of completion rates for items and scales; with missing responses ranging from 5 to 49% (Supplementary Table [3](#MOESM3){ref-type="media"}).

Generic HRQL {#Sec10}
------------

Overall, 65% of respondents reported ≥1 problem on any EQ-5D-5L domain (Table [2](#Tab2){ref-type="table"}). The percentage of respondents from treatment groups reporting ≥1 problem on any EQ-5D-5L domain ranged from 59% for endoscopy/telescopy and intravesical chemotherapy to 74% for radiotherapy. Problems with usual activities were most commonly reported (43%). Respondents treated with radiotherapy reported more problems with mobility, self-care and usual activities compared to respondents who received other treatments. Respondents with endoscopy/telescopy were more likely to report problems with mobility than respondents treated with endoscopy/telescopy and intravesical chemotherapy (47% compared to 26%, *p* \< 0.01).Table 2EQ-5D-5L number of generic health problems and domain responses by demographicDemographicProblems on any EQ5D domainMobilitySelf-careNo problemsProblems*p*-valueNo problemsProblems*p*-valueNo problemsProblems*p*-valueN%N%N%N%N%N%*Age, yearsχ*^2^ = 5.7, *p* = 0.226*χ*^2^ = 41.8, *p* \< 0.01*χ*^2^ = 16.4, *p* \< 0.01 \<552141.23058.84076.91223.14588.2611.8 55--644332.68967.410174.33525.711987.51712.5 65--749239.514160.516468.37631.721087.13112.9 75--845430.912169.18849.29150.814177.04223.0 ≥85926.52573.51234.32365.72367.71132.3*Sexχ*^2^ = 0.2, *p* = 0.651*χ*^2^ = 0.3, *p* = 0.584*χ*^2^ = 0, *p* = 0.911 Male17035.630864.431063.717736.341083.58116.5 Female5133.610166.49861.26238.813383.12716.9*No. of long-term conditionsχ*^2^ = 48.9, *p* \< 0.01*χ*^2^ = 115.9, *p* \< 0.01*χ*^2^ = 81.9, *p* \< 0.01 None5753.35046.79486.21513.810798.221.8 18443.510956.515578.34321.718191.0189.0 24130.19569.98460.45539.612086.31913.7 ≥33117.115082.96333.312666.712062.87137.2*Disease statusχ*^2^ = 17.4, *p* = 0.01*χ*^2^ = 13, *p* \< 0.01*χ*^2^ = 11.5, *p* \< 0.01 Remission17040.425159.628866.814333.237185.96114.1 Treated but cancer still present922.53177.52151.22048.82970.71229.3 Recurrence826.72273.32066.71033.32583.3516.7 Not certain1519.26380.83948.14251.96074.12125.9*Treatmentχ*^2^ = 6.6, *p* = 0.156*χ*^2^ = 31.7, *p* \< 0.01*χ*^2^ = 20.5, *p* \< 0.01 Endoscopy/telescopy6834.512965.510853.59446.516681.03919.0 Endoscopy/telescopy with chemotherapy directly into the bladder8041.511358.514574.05126.017789.92010.1 Radical cystectomy2730.76169.36268.92831.17482.21617.8 Radiotherapy and Intravenous chemotherapy1030.32369.72057.11542.93188.6411.4 Radiotherapy1626.24573.82641.33758.74166.12133.9*Stoma statusχ*^2^ = 1.7, *p* = 0.189*χ*^2^ = 0.2, *p* = 0.622*χ*^2^ = 0.7, *p* = 0.400 Stoma3129.57470.57066.03634.08681.12018.9 No stoma15236.426663.627163.515636.536584.56715.5DemographicUsual activitiesPain/DiscomfortAnxiety/DepressionNo problemsProblems*p*-valueNo problemsProblems*p*-valueNo problemsProblems*p*-valueN%N%N%N%N%N%*Age, yearsχ*^2^ = 21, *p* \< 0.01*χ*^2^ = 7.7, *p* = 0.103*χ*^2^ = 13.3, *p* = 0.01 \<553567.31732.73159.62140.42650.02650.0 55--648462.75037.37454.46245.67656.35943.7 65--7415163.28836.816167.97632.116569.07431.0 75--848747.59652.511864.56535.512569.45530.6 ≥851235.32264.72057.11542.92058.81441.2*Sexχ*^2^ = 3.2, *p* = 0.073*χ*^2^ = 1.9, *p* = 0.169*χ*^2^ = 0, *p* = 0.876 Male29159.419940.630061.219038.831764.617435.4 Female8151.37748.710767.35232.79963.95636.1*No. of long-term conditionsχ*^2^ = 74.4, *p* \< 0.01*χ*^2^ = 41.8, *p* \< 0.01*χ*^2^ = 10.8, *p* = 0.013None8779.12320.98779.82220.27971.83128.2 113367.26532.814069.76130.313267.06533.0 27856.16143.98259.95540.19165.94734.1 ≥36233.012667.08645.510354.510354.88545.2*Disease statusχ*^2^ = 19.6, *p* \< 0.01*χ*^2^ = 18, *p* \< 0.01*χ*^2^ = 16.9, *p* \< 0.01 Remission27163.315736.729267.913832.130170.212829.8Treated but cancer still present2048.82151.22152.51947.51947.52152.5 Recurrence1653.31446.71653.31446.71550.01550.0 Not certain3138.35061.73745.74454.34455.03645.0*Treatmentχ*^2^ = 19.2, *p* \< 0.01*χ*^2^ = 14.3, *p* \< 0.01*χ*^2^ = 2.1, *p* = 0.719 Endoscopy/telescopy12360.08240.014470.66029.413265.47034.6 Endoscopy/telescopy with chemotherapy directly into the bladder13166.86533.213066.76533.312965.56834.5 Radical cystectomy4146.14853.95156.04044.05359.63640.4 Radiotherapy and Intravenous chemotherapy1750.01750.01647.11852.92057.11542.9 Radiotherapy2641.93658.13353.22946.84167.22032.8*Stoma statusχ*^2^ = 6, *p* = 0.014*χ*^2^ = 7.2, *p* \< 0.01*χ*^2^ = 0.1, *p* = 0.807Stoma5147.75652.35450.55349.56762.64037.4 No stoma26060.716839.327764.615235.427663.915636.1

Respondents aged ≥85 years were most likely to report some problems with mobility, self-care and usual activities. Respondents \<55 years old were significantly more likely to report problems with anxiety/depression, with half of this group reporting some problems, compared to between 31--44% of other age groups (*p* = 0.01). Those with ≥3 LTCs reported significantly more problems on all EQ-5D-5L domains bar one (anxiety/depression).

Social difficulties {#Sec11}
-------------------

### SD-16 {#Sec12}

Overall, 15% of respondents were classed as socially distressed (score ≥10, Table [3](#Tab3){ref-type="table"}). No differences were observed by sex or age group. The respondents most likely to report significantly high social distress were those treated with radiotherapy and respondents with ≥3 LTCs; with more than a quarter of respondents from these groups meeting the criteria. Respondents with a stoma were twice as likely to be socially distressed compared to respondents without a stoma.Table 3Social Difficulties Inventory: SD-16 and SDI-21 subscale results by demographicDemographicSocial Distress*p*-valueEveryday Living*p*-valueMoney Matters*p*-valueSelf and Others*p*-valueSDNo SDDifficultyNo difficultyDifficultyNo difficultyDifficultyNo difficultyN%N%N%N%N%N%N%N%*Age, yearsχ*^2^ = 7.8, *p* = 0.098*χ*^2^ = 8.6, *p* = 0.071*χ*^2^ = 57.9, *p* \< 0.01*χ*^2^ = 24.9, *p* \< 0.01 \<551426.43973.61324.54075.52241.53158.51834.03566.0 55--642317.311082.72216.311383.73123.310276.73425.010275.0 65--742912.021288.04418.119981.9239.521890.52911.921488.1 75--842313.814486.24324.013676.0116.515793.52111.915688.1 ≥85516.12683.91235.32264.713.03297.0618.72681.3*Sexχ*^2^ = 0.2, *p* = 0.688*χ*^2^ = 4.7, *p* = 0.031*χ*^2^ = 3.4, *p* = 0.065*χ*^2^ = 0.5, *p* = 0.484 Male7114.841085.29318.940081.17415.341084.78016.341183.7 Female2416.112583.94226.911473.1149.313690.72918.712681.3*No. of long-term conditionsχ*^2^ = 26, *p* \< 0.01*χ*^2^ = 64.7, *p* \< 0.01*χ*^2^ = 4.4, *p* = 0.221*χ*^2^ = 8.2, *p* = 0.041 None65.710094.398.39991.71110.49589.61211.19688.9 12311.917088.12512.317887.72512.817087.23417.116582.9 21813.411686.62518.111381.91712.711787.31913.811986.2 ≥34826.113673.97741.011159.03418.315281.74322.914577.1*Disease statusχ*^2^ = 18.8, *p* \< 0.01*χ*^2^ = 14.9, *p* \< 0.01*χ*^2^ = 5.6, *p* = 0.134*χ*^2^ = 15.2, *p* \< 0.01 Remission4310.337689.77116.535983.54811.437388.65312.437387.6 Treated but cancer still present1024.43175.61229.32970.749.83790.2717.13482.9 Recurrence620.72379.3620.72379.3620.72379.3930.02170.0 Not certain2026.05774.02733.75366.31519.26380.82126.65873.4*Treatmentχ*^2^ = 22.1, *p* \< 0.01*χ*^2^ = 27.7, *p* \< 0.01*χ*^2^ = 7.1, *p* = 0.131*χ*^2^ = 18.1, *p* \< 0.01 Endoscopy/telescopy2311.617688.44723.115676.92311.617688.42612.917687.1 Endoscopy/telescopy with chemotherapy directly into the bladder168.517391.52110.817489.22211.616788.42211.217488.8 Radical cystectomy2123.66876.42325.36874.71719.17280.92527.86572.2 Radiotherapy and Intravenous chemotherapy720.02880.0720.02880.0720.02880.0720.02880.0 Radiotherapy1628.14171.92440.73559.346.95493.11525.44474.6*Stoma statusχ*^2^ = 9.4, *p* \< 0.01*χ*^2^ = 1.1, *p* = 0.293*χ*^2^ = 3.3, *p* = 0.068*χ*^2^ = 6, *p* = 0.014 Stoma2422.68277.42523.18376.92018.98681.12624.18275.9 No stoma4811.237988.88118.735381.35212.137787.96214.337185.7

### SDI-21 subscales {#Sec13}

Difficulties with Everyday Living (score ≥5) were reported by 21% of respondents (Table [3](#Tab3){ref-type="table"}). Respondents treated with radiotherapy and those who had ≥3 LTCs reported a higher level of difficulty with Everyday Living (both 41%). Comparatively fewer patients receiving other treatments reported difficulties (≤25%). When comparing patients who did not have radical treatments, significantly more respondents with endoscopy/telescopy reported difficulties with Everyday Living than respondents treated with endoscopy/telescopy and intravesical chemotherapy (23% compared to 11%, *p* \< 0.01). Difficulties with Everyday Living did not vary by sex, age group or stoma status.

Difficulties with Money Matters (score ≥2) were reported by 14% of respondents. This difficulty was significantly more likely to be reported by respondents who were \<55 years of age (42% compared to between 3 and 23% of other age groups, *p* \< 0.01). Differences were not found for treatment type, disease status, stoma status, LTCs or sex (Table [3](#Tab3){ref-type="table"}).

Difficulties with Self and Others (score ≥3) were reported by 17% of respondents. Reporting of significant difficulties with Self and Others was high in respondents \<55 years of age, where more than a third (34%) reported difficulties (Table [3](#Tab3){ref-type="table"}).

### SDI-21 single items {#Sec14}

The most commonly reported difficulty was with travelling or plans to take a holiday; reported by 33% of respondents. Respondents with a stoma were significantly more likely to report \'quite a bit\' or \'very much\' difficulty with this item than those without a stoma (29% compared to 15%, *p* \< 0.01).

Difficulties with sexual matters were reported \'quite a bit\' or \'very much\' by 15% of respondents. This difficulty was significantly more likely to impact on men, 17% of whom reported \'quite a bit\' or \'very much\' difficulty compared to 5% of females (*p* \< 0.01).

Cancer-specific HRQL {#Sec15}
--------------------

### Physical well-being {#Sec16}

Overall, 25% of the cohort responded that they experienced a lack of energy \'quite a bit\' or \'very much\', but this was higher in respondents treated with radiotherapy (43%) (Table [4](#Tab4){ref-type="table"}).Table 4Cancer-specific patient-reported outcomes by treatment groupEndoscopy/telescopyEndoscopy/telescopy with chemotherapy directly into the bladderRadical cystectomyRadiotherapy and Intravenous chemotherapyRadiotherapy*p*-valueNot at all/somewhatQuite a bit/very muchNot at all/somewhatQuite a bit/very muchNot at all/somewhatQuite a bit/very muchNot at all/somewhatQuite a bit/very muchNot at all/somewhatQuite a bit/very muchN%N%N%N%N%N%N%N%N%N%*Physical well-being* I have a lack of energy15076.94523.115583.33116.76878.21921.82573.5926.53456.72643.3*χ*^2^ = 18.4, *p* \< 0.01 Because of my physical condition, I have  trouble meeting the needs of my family16290.5179.517396.173.97788.51011.52987.9412.13978.01122.0*χ*^2^ = 16.7, *p* \< 0.01 I have pain16591.2168.816591.7158.37890.789.33090.939.14581.81018.2*χ*^2^ = 5.1, *p* = 0.280*Social/family well-being* I feel close to my friends7242.99657.15130.011970.02327.76072.31647.11852.92345.12854.9*χ*^2^ = 12, *p* = 0.017 My family has accepted my illness3620.713879.32111.915688.167.17992.9514.72985.3610.94989.1*χ*^2^ = 10.9, *p* = 0.027 I am satisfied with my sex life6060.63939.46859.74640.34488.0612.01164.7635.31773.9626.1*χ*^2^ = 14.8, *p* \< 0.01*Emotional well-being* I feel sad10088.51311.512191.0129.05785.11014.91885.7314.32987.9412.1*χ*^2^ = 1.8, *p* = 0.781 I am satisfied with how I am coping with my illness4434.98265.13021.610978.41520.55879.5521.71878.31129.72670.3*χ*^2^ = 8.1, *p* = 0.087 I feel nervous10686.21713.812490.5139.56490.179.92195.514.53297.013.0*χ*^2^ = 4.5, *p* = 0.343 I worry about dying11289.61310.412992.1117.96390.0710.02090.929.13294.125.9*χ*^2^ = 1, *p* = 0.907 I worry that my condition will get worse16686.92513.116387.22412.87586.21213.82163.61236.44783.9916.1*χ*^2^ = 13.3, *p* = 0.01*Functional well-being* I am able to work (include work from home)6335.811364.24726.513073.53136.55463.51136.71963.32858.32041.7*χ*^2^ = 17.2, *p* \< 0.01 My work (include work at home) is fulfilling5633.910966.14828.612071.43138.35061.7828.62071.42657.81942.2*χ*^2^ = 14.3, *p* \< 0.01 I am able to enjoy life4624.514275.53216.815983.22224.76775.326.13193.91728.84271.2*χ*^2^ = 10.7, *p* = 0.03 I am sleeping well6634.212765.85228.013472.02932.26167.81235.32264.71831.04069.0*χ*^2^ = 2, *p* = 0.739 I am enjoying the things I usually do for fun5328.513371.53720.014880.02529.16170.91133.32266.72138.93361.1*χ*^2^ = 9.5, *p* = 0.049 I am content with the quality of my life right now5227.713672.33417.815782.22832.25967.81030.32369.71628.64071.4*χ*^2^ = 9.2, *p* = 0.057*Bladder cancer-specific items* I have control of my bowels4221.615278.42513.016787.02023.06777.0515.12884.91424.14475.9*χ*^2^ = 7.6, *p* = 0.107 I urinate more frequently than usual12765.56734.512062.87137.2NANANANA1750.01750.02955.82344.2*χ*^2^ = 4, *p* = 0.264 I have a good appetite4321.715578.32513.016787.01922.16777.9411.43188.61423.74576.3*χ*^2^ = 8.2, *p* = 0.085 It burns when I urinate17993.7126.316591.2168.8NANANANA2985.3414.75393.047.0*χ*^2^ = 3.1, *p* = 0.377 I am interested in sex11065.95734.110660.27039.85571.42228.62371.9928.13981.3918.7*χ*^2^ = 9.1, *p* = 0.059 (For men only) I am able to have and maintain an erection9166.44633.67659.85140.25294.535.51789.5210.53489.5410.5NA

Pain was reported \'quite a bit\' or \'very much\' by 10% of respondents and was higher in respondents with ≥3 LTCs (19%) (Table [5](#Tab5){ref-type="table"}).Table 5Cancer-specific patient-reported outcomes by number of long-term conditions (LTCs)No LTC1 LTC2 LTCs≥3 LTCs*p*-valueNot at all/somewhatQuite a bit/very muchNot at all/somewhatQuite a bit/very muchNot at all/somewhatQuite a bit/very muchNot at all/somewhatQuite a bit/very muchN%N%N%N%N%N%N%N%*Physical well-being* I have a lack of energy9791.598.517085.92814.19876.03124.010155.58144.5*χ*^2^ = 66, *p* \< 0.01 Because of my physical condition, I have trouble meeting the  needs of my family10498.121.917091.9158.111694.375.713280.03320.0*χ*^2^ = 29.8, *p* \< 0.01 I have pain10197.132.917594.6105.410987.21612.813881.23218.8*χ*^2^ = 24.9, *p* \< 0.01*Social/family well-being* I feel close to my friends2627.46972.66435.411764.64639.37160.76641.09559.0*χ*^2^ = 5.3, *p* = 0.150 My family has accepted my illness1413.68986.42513.815686.22016.310383.71810.814889.2*χ*^2^ = 1.8, *p* = 0.609 I am satisfied with my sex life3956.53043.57161.74438.34875.01625.06776.12123.9*χ*^2^ = 10, *p* = 0.018*Emotional well-being* I feel sad7094.645.412894.185.97488.11011.98676.12723.9*χ*^2^ = 22.9, *p* \< 0.01 I am satisfied with how I am coping with my illness1620.86179.23121.811178.22223.77176.34736.28363.8*χ*^2^ = 9.5, *p* = 0.023 I feel nervous7397.322.713394.385.78493.366.79579.22520.8*χ*^2^ = 24.9, *p* \< 0.01 I worry about dying6990.879.213293.696.48594.455.610483.92016.1*χ*^2^ = 9.6, *p* = 0.023 I worry that my condition will get worse9185.81514.216686.52613.511387.61612.414581.03419.0*χ*^2^ = 3.3, *p* = 0.348*Functional well-being* I am able to work (include work at home)1818.08282.03821.314078.75342.77157.38753.77546.3*χ*^2^ = 55.6, *p* \< 0.01 My work (include work at home) is fulfilling2021.57378.54426.012574.04336.87463.27751.37348.7*χ*^2^ = 31.2, *p* \< 0.01 I am able to enjoy life1615.09185.02914.716885.32519.410480.66033.711866.3*χ*^2^ = 24.3, *p* \< 0.01 I am sleeping well2321.98278.15226.814273.24433.18966.97541.910458.1*χ*^2^ = 15.5, *p* \< 0.01 I am enjoying the things I usually do for fun1615.78684.33116.216083.83427.29172.87945.49554.6*χ*^2^ = 47.7, *p* \< 0.01 I am content with the quality of my life right now2220.48679.62814.616485.43829.98970.16737.411262.6*χ*^2^ = 28.2, *p* \< 0.01*Bladder cancer-specific items* I have control of my bowels1413.39186.73015.316684.72720.310679.74525.013575.0*χ*^2^ = 8.3, *p* = 0.04 I urinate more frequently than usual7370.93029.111763.66736.48770.73629.39955.67944.4*χ*^2^ = 10, *p* = 0.019 I have a good appetite1312.19487.93116.016384.02115.811284.25026.913673.1*χ*^2^ = 13, *p* \< 0.01 It burns when I urinate9998.022.017492.6147.412094.575.515389.01911.0*χ*^2^ = 8.5, *p* = 0.036 I am interested in sex5254.24445.89858.07142.08269.53630.513077.83722.2*χ*^2^ = 21.8, *p* \< 0.01 (For men only) I am able to have and maintain an erection4261.82638.28766.44433.67578.12121.910782.92217.1*χ*^2^ = 15.1, *p* \< 0.01

### Social/family well-being {#Sec17}

Of the 51% who answered this item, two thirds (67%) reported dissatisfaction with their sex life (\'not at all\' or \'a little\' satisfied with their sex life). Dissatisfaction was significantly more likely to be reported by patients who underwent RC surgery compared to those who had other treatments (Table [4](#Tab4){ref-type="table"}). A higher percentage of females reported that they were \'quite a bit\' or \'very much\' satisfied with their sex life (51% compared to 31% of males, *p* \< 0.01).

### Emotional well-being {#Sec18}

Respondents across the cohort reported a lack of satisfaction with how they were coping with their illness, as almost three-quarters of respondents reported that they were \'not at all\' or \'a little\' satisfied. Feeling \'quite a bit\' or \'very much\' nervous was reported by 10% of respondents; particularly by females (18% compared to 7% of males, *p* \< 0.01), and those with ≥3 LTCs (Table [5](#Tab5){ref-type="table"}).

### Functional well-being {#Sec19}

Around a third of respondents (35%) answered \'not at all\' or \'a little\' about their ability to work. Respondents treated with radiotherapy were less likely to be able to work compared to respondents receiving other treatments (Table [4](#Tab4){ref-type="table"}).

Although three quarters of respondents reported that they were content with the quality of their life right now (reporting \'quite a bit\' or \'very much\'), respondents with ≥3 LTCs were significantly more likely to report that they were not content (Table [5](#Tab5){ref-type="table"}).

### Bladder cancer-specific items {#Sec20}

#### Urinary items {#FPar1}

Urinating more frequently than usual was common after endoscopy (reported \'quite a bit\' or \'very much\' in 34--37%) and radiotherapy (reported \'quite a bit\' or \'very much\' in 44--50%) (Table [4](#Tab4){ref-type="table"}).

#### Sexual items {#FPar2}

Disinterest in sex was reported by 66% of respondents and had a good response rate of 85%. Disinterest in sex was significantly higher in females than males, with 86% of females saying they were \'not at all\' or only \'a little\' interested in sex, compared to 60% of males (*p* \< 0.01). This difference was observed (but not significant due to small numbers) when restricted to those who had a stoma, with 89% of females saying they were \'not at all\' or only \'a little\' interested. Ability to maintain an erection was less likely in males who had a stoma, with 96% reporting \'not at all\' or \'a little\' to this item, though the result was not significant due to small numbers.

#### Body image {#FPar3}

Just under half of respondents said that they didn't like their body appearance at all, or only liked it a little (48%). Respondents with a stoma were more likely to report not liking their body at all or only liking it a little (60% compared to 46% of respondents without a stoma, *p* = 0.01).

Discussion {#Sec21}
==========

Here we report HRQL in individuals between 1 and 5 years post diagnosis for BC. While modest in size compared to PROMs studies in other cancer sites, this work represents the largest UK study to date and demonstrates this methodology is feasible in this population. We have identified that reduced HRQL is common in patients following BC treatment, that there are differences according to treatment modality and patient characteristics, and that further more focused studies are warranted.

Several key findings deserve discussion. First, our results highlight the need to support people who have pre-existing health conditions and a new diagnosis of BC. Respondents with LTCs were much more likely to report poor HRQL across all EQ-5D-5L items, all domains apart from Money Matters on the SDI-21, SD-16 and on multiple items of FACT-Bl. The design and methodology used in this survey limits our ability to investigate this further and to understand whether this reflects the impact of BC on other LTCs, or the impact of other LTCs on HRQL. This is an important area for future studies to focus on.

Second, while we do not know details of each tumour (i.e., stage or grade), most patients (60%) received only endoscopic surgery. To date, most BC HRQL reports have focused upon MIBC and cystectomy outcomes. As such, our data are the first to look at HRQL in MIBC and NMIBC outcomes across a UK population. When comparing NMIBC treatments, overall, respondents receiving endoscopic surgery with intravesical chemotherapy had higher HRQL and fewer everyday living difficulties than those receiving only endoscopic surgery. This may reflect recall bias (guidelines suggest that most patients should have received intravesical chemotherapy),^[@CR4]^ performance status (unfit patients did not receive intravesical chemotherapy), treatment differences (intravesical chemotherapy improves disease outcomes) or service design (perhaps better designed services are more guideline compliant and more likely to support patients through treatment). Support for patient selection has shown that for many domains the HRQL was superior for combined treatment rather than just endoscopic surgery.

Third, around 30% of respondents received radical therapy, including 16% who had a stoma and 9% who had received radiotherapy. The latter were most likely to report low HRQL, problems with mobility, self-care and usual activities. They were also more likely to be socially distressed (score ≥10 on SD-16), have high levels of difficulty with everyday living, report a lack of energy and an inability to work. Patients treated with radiotherapy were also more likely to report needing to urinate more frequently than usual. While these findings may reflect outcomes from radiotherapy, when compared to RC, it is more likely they reveal treatment patterns and pre-existing fitness.^[@CR26]^ Evidence to support this is that most of these measures were better for patients who received both radiotherapy with chemotherapy (for which higher fitness is needed). Indeed outcomes from RC and radiotherapy with chemotherapy were broadly comparable to each other and to patients receiving only endoscopy/telescopy.^[@CR27]^ Finally, overall there were some encouraging findings with social distress generally being low in respondents, as 85% were below the cutoff point, and perfect health (i.e., no problems on EQ-5D-5L) was reported by 35% of respondents.

This study has a number of key limitations. Response rates were marginally lower than for UK surveys in other cancer sites (63% for colorectal cancer)^[@CR14]^ and 68% overall for a pilot study of individuals diagnosed with non-Hodgkin's lymphoma (62%), breast (68%), colorectal (64%) and prostate cancer (69%)).^[@CR17]^ This may reflect the BC population (i.e., typically more deprived, more manual workers and lower literacy rates than other cancers).^[@CR28]^ While respondents were willing to answer personal questions, response rates for sexual items were lower than for other domains. Details of disease stage were not available and treatment details were self-reported (and not verified from other sources) thereby reducing ability to interpret data in detail.

A major limitation was the removal by the survey developers of the \'somewhat\' response option from the FACT-Bl questionnaire, which meant that composite scores could not be calculated, thus affecting the interpretation of results. Although the removal of response options from validated measures is not considered good measurement practice, we were still able to gain important information about patients who had few or no problems and patients who had severe problems with individual items. Despite this limitation, it was considered important to present the findings as there is a lack of large-scale studies looking at all BC populations. A further limitation was that, as it was a pilot study, the sample was randomly identified, rather than population-based.

The results have been presented descriptively and multivariable analysis was not undertaken. The small number of respondents in some subgroups (e.g., in some of the treatment groups) and the lack of information on important confounders (such as a measure of socioeconomic deprivation) make it difficult to obtain robust, meaningful results.

Although more detailed analysis could not be carried out in this study, it is important that future studies aim to incorporate this. In particular, quantifying the impact of treatment-related issues (e.g., urinary, bowel, sexual problems or fatigue) on HRQL and social distress is hugely important, as this will further highlight the support and care needs of this group of patients, and indicate where there are gaps in service provision.

Recent qualitative work highlighted gaps in the understanding of HRQL of BC patients (particularly patients with NMIBC).^[@CR12]^ Important themes included post-treatment experiences in terms of family/friend support networks, dealing with incontinence, voiding and catheterising, the \'new normal\' (e.g., coping with their post-surgery body), changing sexuality and living with the lifelong threat of cancer.^[@CR12]^ Although the authors recommend longitudinal qualitative work with BC patients, based on the results of the DH study, there is also a need to undertake quantitative work to understand how HRQL changes in BC patients over time. Future work should aim to identify both high risk groups and treatment-related items with the biggest impact on HRQL. This could potentially lead to PROMs being used as part of routine practice, with risk factors for low HRQL monitored in clinic.

A further recommendation for future BC PROMs work using FACT-Bl is to include some validation work within the analysis. Although FACT-G is widely considered to be a reliable and valid tool to use with cancer patients, the bladder cancer-specific items require psychometric analysis to understand how useful these items are for use with BC populations. Alternatively, clinicians and researchers may choose other BC specific measures, such as the Bladder Cancer Index (BCI),^[@CR29]^ or the European Organisation for Research and Treatment of Cancer (EORTC) NMIBC and MIBC modules.^[@CR30],[@CR31]^

These data represent the largest PROMs study to use BC specific PROMs. The results have highlighted groups at high risk of significant adverse consequences following BC diagnosis. However, there is a need to carry out larger in-depth population-based HRQL studies of BC patients to fully understand the extent of the morbidity burden experienced by survivors of BC.
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